Precision BioSciences Collects $7.5M Milestone Payment for MS Gene Therapy
Event summary
- Precision BioSciences received $7.5 million from TG Therapeutics related to the clinical progress of azer-cel, a gene therapy for multiple sclerosis.
- The payment includes $5.25 million in cash and $2.25 million in Precision BioSciences common stock.
- The milestone was triggered by progress in a Phase 1 clinical trial of azer-cel for progressive forms of multiple sclerosis.
- Precision BioSciences anticipates the proceeds, combined with existing resources, will support operations through 2028.
- The license agreement grants TG Therapeutics exclusive worldwide rights to develop and commercialize azer-cel for autoimmune diseases.
The big picture
This milestone payment provides Precision BioSciences with a near-term financial boost, but the company's long-term success hinges on the clinical validation of azer-cel and the broader adoption of its ARCUS platform. The deal highlights the growing trend of gene editing companies leveraging partnerships to accelerate development and share risk, particularly in areas like autoimmune disease where traditional therapies often fall short.
What we're watching
- Clinical Efficacy
- The Phase 1 trial data for azer-cel will be critical in determining the therapy’s potential and influencing future development decisions, and will likely dictate the timing and size of subsequent milestone payments.
- Financial Stability
- Precision BioSciences’ ability to extend its cash runway through 2028 will depend on continued milestone payments from TG Therapeutics and potentially other financing activities.
- Partnering Strategy
- The success of the TG Therapeutics partnership will shape Precision BioSciences’ approach to licensing its ARCUS platform and seeking external funding for its in vivo gene editing pipeline.
Related topics